PACTR201711002680100已完成未知
An Exploratory Phase I, Randomised, Open-Label, 3-Way Cross-over, Single Centre Study In Healthy Subjects To Investigate The Pharmacokinetics Of An Inhaled Formulation Of Fluticasone Propionate And Salmeterol (As Xinafoate) 250/25 ¿g Delivered Via Two Different Inhalation Devices, Compared To A Reference Product
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Year(s) 至 100 Year(s)（—）
- 性别
- All
入选标准
- •1. Healthy male and female subjects, 18 years and older; 2. Body mass index (BMI) between 18.5 and 30 kg/m2 (both inclusive); 3. Body mass not less than 50 kg for males and 55 kg for females; 4. Medical history, vital signs, physical examination, standard 12 lead electrocardiogram (ECG) and laboratory investigations must be clinically acceptable or within laboratory reference ranges for the relevant laboratory tests, unless the Investigator considers the deviation to be irrelevant for the purpose of the study; 5. Non-smokers; 6. Females, if: Not of childbearing potential, e.g., been surgically sterilised, undergone hysterectomy, amenorrhea for >12 months and considered post menopausal; OR Of childbearing potential, following conditions to be met: Negative pregnancy test; If test positive, subject will be excluded from study. In rare circumstance that pregnancy discovered after subject receives IMP, every attempt must be made to follow her to term; Not lactating; Abstaining from sexual activity (if this is usual lifestyle of subject) or must agree to use accepted method of contraception, and agree to continue with same method throughout the study; Examples of reliable methods of contraception include non hormonal intrauterine device, barrier methods combined with additional contraceptive method; Other methods, if considered by the Investigator as reliable, will be accepted; 7. Subjects with normal potassium levels (according to local laboratory reference ranges); 8. Written consent given for participation in the study.
排除标准
- •1. Psychiatric disorder or emotional, personality or intellectual problems likely to limit ability to consent or comply with study requirements; 2. Excess alcohol use; 3. Regular exposure to substances of abuse (other than alcohol) within past year; 4. Use within 2 weeks before IMP administration of any medication or other remedies that may interfere with the conduct or results of the study; 5. Concomitant use of hormonal replacement therapy or hormonal contraceptives; 6. Participation in a clinical investigation within 8 weeks before IMP administration in this study; 7. Use of any drug with well-defined potential for adversely affecting any organ or system, within 3 months before IMP administration; 8. Major illness in 3 months before start of screening; 9. History of hypersensitivity or allergy to IMP, excipients or related medication; 10. History of asthma or other bronchospastic disease; 11. History of epilepsy, porphyria, or current cataracts or glaucoma; 15. History of oral candida requiring treatment in last 3 years; 16. History, laboratory or clinical findings indicative of disease likely to influence study outcomes; 17. Conditions causing hypokalemia; 18. Blood loss equal to or exceeding 500 mL within 8 weeks before IMP administration; 19. Hypotension diagnosed at screening; 20. Current hypertension or diagnosis at screening; 21. Resting tachy- or bradycardia at screening; 22. Positive HIV, Hepatitis B or Hepatitis C tests; 23. Positive urinary drugs of abuse or cotinine; 24. Positive pregnancy test; 25. Inadequate inhalation technique at screening; 26. FEV1 < 80% predicted value; 27. Immunisation with live vaccine within 4 weeks before IMP administration; 28. Vulnerable subjects.
研究者
相似试验
进行中（未招募）
不适用
A phase IIIb, open label, randomized, exploratory clinical study exploring efficacy, safety and patients’ satisfaction with Certolizumab pegol treatment in moderate to severe Crohn’s disease when treatment is administered in two different settings : either at hospital or at home - PERFECTCrohn's diseaseMedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's diseaseEUCTR2007-003239-21-FRCB PHARMA S.A.
尚未招募
2 期
A Study to evaluate the Efficacy and Tolerability of ActiTape in Patients with Pain in Knee Joint due to Mild to Moderate OsteoarthritisCTRI/2013/02/003402utriworks Limited14
已完成
3 期
study of drug (rhoclone) on Rh negative blood group mother giving birth to Rh positive blood group babyCTRI/2015/09/006172Bharat Serums Vaccines Limited
尚未招募
1 期
Evaluation of Equine antibody treatment in patient with COVID 19 infectioCTRI/2021/06/034359Serum Institute of India Pvt Ltd
已完成
3 期
CLINICAL TRIAL OF TIAPRIDE TO EVALUATE ITS SAFETY AND EFFECTIVENESS IN THE TREATMENT OF AGITATION AND AGGRESSIVENESS IN ADULT AND ELDERLY PATIENTS WITH IMPAIRED HIGHER MENTAL FUNCTIONSCTRI/2010/091/000176Intas Pharmaceuticals Limited240